AbbVie: European Commission Approves Rinvoq to Treat Active Psoriatic Arthritis
By Stephen Nakrosis
AbbVie Inc. on Monday said the European Commission approved
Rinvoq to treat psoriatic arthritis and ankylosing spondylitis.
The company said Rinvoq, or upadacitinib, was approved to treat
active psoriatic arthritis in adult patients who have responded
inadequately to, or who are intolerant to one or more
disease-modifying antirheumatic drugs.
Rinvoq was also indicated to treat active ankylosing spondylitis
in adult patients who have responded inadequately to conventional
therapy, AbbVie said.
The company said Rinvoq is the "first oral, once-daily,
selective and reversible JAK inhibitor approved for three adult
rheumatic indications in the European Union: rheumatoid arthritis,
psoriatic arthritis and ankylosing spondylitis."
The company said approval was supported by data from three
clinical studies which saw Rinvoq meeting all primary and key
secondary endpoints with a safety profile consistent with that seen
in rheumatoid arthritis.
Write to Stephen Nakrosis at firstname.lastname@example.org
(END) Dow Jones Newswires
January 25, 2021 12:29 ET (17:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.